Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We therefore investigated the functions, mechanisms, and clinical significance of TAMs in colorectal cancer.<b>Experimental Design:</b> We measured the macrophage infiltration (CD68), P-gp, and Bcl2 expression in colorectal cancer tissues using IHC staining.
|
28928161 |
2017 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Bcl-2 rs1800477A/G polymorphism may be related to the occurrence of CRC, and GG genotype could be a risk factor of poor prognosis in CRC.
|
28106544 |
2017 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, stable knockdown of β4-integrin in human CRC SW620 cells reduces Bcl-2 expression, increases apoptosis, and decreases invasion, tumorigenicity, and liver metastasis, thus resulting in significantly increased survival of mice (hazard ratio = 0.32, 95% confidence interval = 0.15-0.66, P<0.01).
|
29190919 |
2017 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present work provides the first evidence of a UCA1-miR-204-5p-CREB1/BCL2/RAB22A regulatory network in CRC and reveals that UCA1 and CREB1 are potential new oncogenes and prognostic factors for CRC.
|
27046651 |
2016 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, we found that miR-139-5p targeted the BCL2 pathway to reduce tumour metastasis and drug sensitivity in CRC.
|
27244080 |
2016 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Human CRC tissue was cultured ex vivo and treated with the small molecule compound ABT-737, which inhibits Bcl-xL and Bcl-2.
|
27537525 |
2016 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Consequently, the expression level of Hh/Gli2 pathway-related apoptotic protein Bcl-2 was decreased and the function of resisting cell death was inhibited in CRC.
|
28032859 |
2016 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
As expected, decreased levels of Bcl‑2 and increased levels of Bax were detected in the HMGB1 shRNA‑transfected colorectal cancer cells, and the Bax/Bcl‑2 ratio was increased in HMGB1 shRNA‑transfected cells.
|
27220399 |
2016 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since CRC comprises heterogeneous tumors with predominant hypoxic components, we investigated effects of an inhibitor of anti-apoptotic Bcl-2 family proteins (ABT-737) in combination with an mTOR inhibitor (AZD8055)-collectively referred to as combo-Rx, in hypoxic CRC cell lines.
|
27461218 |
2016 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Neither Bcl-2 or β-catenin were shown to be useful biomarkers for the prognosis of colorectal cancer.
|
25738398 |
2015 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We thus hypothesized that pPXN-Y31/Y118 may be required for Bcl-2 protein stability via PXN interacting with Bcl-2 to confer 5-FU resistance in colorectal cancer.
|
25323586 |
2015 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Arginine methyltransferase inhibitor 1 (AMI-1)strongly inhibited tumor growth, increased the ratio of Bax/Bcl-2, and induced apoptosis in mouse CRC xenograt model.
|
26078354 |
2015 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Three of those (COL1A2, SFRP2, SOCS3) showed hypermethylation and THBS2 showed hypomethylation both in AD and in CRC samples compared to NAT, while BCL2, PRIMA1 and PTGDR showed hypermethylation only in the CRC group. miR-21 was found to be significantly (p < 0.01) upregulated in adenoma and tumour samples compared to the healthy colonic tissue controls and could explain the altered expression of genes for which DNA methylation changes do not appear to play role (e.g.BCL2, MAL, PTGS2).
|
26482433 |
2015 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
DNA flow cytometry and immunostaining of p53, bcl-2, and c-myc were carried out on 36 cases of CRC radical resection specimens with their corresponding LN metastases.
|
25840688 |
2015 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In summary, our results show that rs7911488 C-allelic pre-miR-1307 binds to MBNL1 and infers with Dicer processing, leading to reduced miR-1307 and increased Bcl2 expression, thus representing an important process in the initiation of CRC.
|
25977444 |
2015 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry staining was used to assess the expression of paxillin and its association with the expression of carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, p53 and Bcl-2 in 102 patients with primary colorectal carcinoma.
|
24451945 |
2014 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study revealed functional and mechanistic links between miRNA-30b and oncogene KRAS, PIK3CD and BCL2 in the pathogenesis of CRC.
|
24293274 |
2014 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified three significantly associated mRNA-miRNA pairs: BCL2 was positively associated with miR-16 and SMAD4 was positively associated with miR-567 in the CRC tissue, while MSH6 was positively associated with miR-142-5p in the normal tissue.
|
24895601 |
2014 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This may be explained by the fact that miR-204-5p increases in colorectal cancer cases in order to inhibit increased activity of LC3B-II in autophagy and Bcl2 against apoptosis posttranscriptionally and to take role as tumor suppressor.
|
25209181 |
2014 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In vivo, the inhibition rates of 20, 40, and 80 mg/mL VB on CRC xenograft tumor weight were 42.79%, 53.90%, and 60.99%, respectively, and were accompanied by increased expression of HIPK2, p53, and Bax, and decreased Bcl-2 expression in treated tumors.
|
25282590 |
2014 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Low levels of Smad4 expression in CRC tissues correlated with higher levels of Bcl-2 and Bcl-w and with poor overall survival as observed in immunohistochemical staining of tissue microarrays.
|
24384683 |
2014 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Even though small molecules targeting Bcl-2 proteins are in clinical trials, little is known regarding their effects on CRC.
|
25192188 |
2014 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High levels of BCL-2 family members in colorectal carcinoma cause resistance to treatment.
|
25208882 |
2014 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
JMJD2B silencing induced CRC cell apoptosis via a decrease of the anti-apoptotic gene Bcl-2 family expression, leading to the translocation of Bak and Bax proteins and the promotion of mitochondrial membrane disruption, resulting in the release of cytochrome C from mitochondria and subsequent caspase-9 and caspase-3 cleavage.
|
24957706 |
2014 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Herein, we demonstrated that APRIL depletion by using RNA interference in human colorectal cancer (CRC) COLO 205 and SW480 cells resulted in cell proliferation inhibition and evoked cell cycle arrest in G0/G1 phase and apoptosis, coupled with decrease in CDK2, Cyclin D1, Bcl-2 expression and an increase of p21 and Bax expression.
|
23867993 |
2013 |